{"changes":[],"country":"US","description":"Sidewinder Therapeutics is a San Diego clinical-stage biotech developing precision bispecific antibody-drug conjugates for hard-to-treat solid tumors. It targets squamous-cell carcinomas of lung and head/neck and gastrointestinal cancers. The ADCs bind receptor co-complexes on tumor cells; a $137M Series B takes the lead to clinic in 2027.","domain":"sidewinder-tx.com","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego, US","name":"Sidewinder Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":137000000,"currency":"USD","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"sidewinder-tx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},{"fact":"existence","publisher":"sidewinder-tx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://sidewinder-tx.com"},{"fact":"description","publisher":"sidewinder-tx.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://sidewinder-tx.com"}],"stage":"series-b+","techStack":[],"totalRaisedUsd":200000000,"updatedAt":"2026-06-17"}